Tamoxifen for the Treatment of Myeloproliferative Neoplasms: A Phase II Clinical Trial and Exploratory Analysis

[Nature Communications] TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable myeloproliferative neoplasms, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20%.

A Prospective, Multicenter Study on Hematopoietic Stem-Cell Mobilization with Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor and ‘On-Demand’ Plerixafor in Multiple Myeloma Patients Treated with Novel...

[Haematologica] 301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.

Bidirectional Interplay between Metabolism and Epigenetics in Hematopoietic Stem Cells and Leukemia

[EMBO Journal] The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.

MorphoSys, after Saying AbbVie ‘Failed,’ Defends Own Mixed Blood Cancer Data, Plots Approval Filings

[FierceBiotech] The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.

First-Line Osimertinib for Previously Untreated Patients with NSCLC and Uncommon EGFR Mutations

[Jama Oncology] The Phase II nonrandomized clinical trial enrolled 42 patients with uncommon EGFR mutations, of whom 40 were eligible.

Epoxyeicosatrienoic Acids Alleviate Alveolar Epithelial Cell Senescence by Inhibiting Mitophagy through NOX4/Nrf2 Pathway

[Biomedicine & Pharmacotherapy] Investigators observed that bleomycin induced enhanced mitophagy accompanied by increased mitochondrial ROS content in the murine alveolar epithelial cell line MLE12.

Molecular Monitoring of Lung Allograft Health: Is It Ready for Routine Clinical Use?

[European Respiratory Review] The authors look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use.

CircTENM3 Inhibites Tumor Progression via the miR-558/RUNX3 Axis in Prostate Cancer

[Journal of Translational Medicine] CCK8 assays, EdU assays, Scratch assay and Transwell migration assay were conducted to detect the role of circTENM3 in prostate cancer cells in vitro.

Extensive Elimination of Acinar Cells During Normal Postnatal Pancreas Growth

[Cell Reports] Investigators demonstrated that early postnatal growth of the pancreas unexpectedly involves massive acinar cell elimination.

High CTCF Expression Mediated by FGD5-AS1/miR-19a-3p Axis Is Associated with Immunosuppression and Pancreatic Cancer Progression

[Heliyon] Researchers examined the CCCTC-binding factor (CTCF) function in pancreatic cancer (PC) and discovered that CTCF expression in PC tissues was significantly raised compared to neighboring healthy tissues.

Suppression of the KRAS-NRF2 Axis Shifts Arginine into the Phosphocreatine Energy System in Pancreatic Cancer Cells

[iScience] Unbiased transcriptome and metabolome analyses showed that PDAC cells with disrupted KRASG12D-NRF2 signalling (NRF2−/− cells) shift from aerobic glycolysis to metabolic pathways fed by amino acids.

Knockdown of TACC3 Inhibits Tumor Cell Proliferation and Increases Chemosensitivity in Pancreatic Cancer

[Cell Death & Disease] The authors found that high TACC3 expression in PDAC is associated with poor prognosis. shRNA-mediated TACC3 knockdown caused S phase arrest of the cell cycle and inhibited proliferation in PDAC cell lines.